Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 

    We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

     

    Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Currently, study 1719 is available. Please contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • **Freelancers Wanted**

    Freelancers, participate in a research study at Prism Research and earn extra income while completing your freelance projects in our comfortable facility by participating in one of our many research studies. If you're 18 - 60, healthy and have a flexible schedule, Prism Research has several current and upcoming FDA Approved Studies for you to consider. 

    Participants will receive health examinations and blood tests at no charge, meals and compensation ranging from $900 to $3,500 (or more) for study participation time. 

    Call for more information if you:
    � Currently Live in Minnesota or Western Wisconsin
    � Have Flexibility To Work Remotely
    � Want to Earn Extra Income

    *Interested in learning more about what clinical research studies are available? Reply or call Lindsay, Recruitment Coordinator at (651) 368-3360.

    Located in St. Paul

     

    Register in the database here

     

  • Study 1620: Male and Female Participants with Atopic Dermatitis

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed to treat subjects who have moderate to severe Atopic Dermatitis.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure Women with tubal ligation or bilateral salpingectomy if willing to use an acceptable method of contraception, or women of child bearing potential using acceptable forms of birth control are allowed to participate.

    Age

    18-70 years

    Body Mass Index (BMI)

    Between 17.5 – 38.0 kg/m²

    Body Weight

    Total body weight >50 kg (110 lbs).

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must have moderate to severe Atopic Dermatitis

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for at least 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research four times for a 4-hour period of study drug administration.

    Clinic Visits

    • There are up to 15 outpatient clinic visits, including screening

    Compensation for participation time:   Up to $1965.00 for approximately 15 visits

    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements

    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits

    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

  • Study 1718 Healthy Female and Male Participants NEW DATES ADDED

    Research Purpose: To evaluate how one drug interacts with an investigational drug being developed for the treatment of certain types of cancers.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate and must use acceptable birth control.

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women using an acceptable method of birth control are allowed to participate.

    Age

    18-55 years of age

    Weight/Body Mass Index (BMI)

    BMI between 18-30 kg/m²

    Tobacco/Nicotine Use

    Subjects must not have used tobacco or tobacco containing products, more frequently than 5 cigarettes per week within 2 months prior to screening or anytime within the week before screening and throughout the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Medications

    No use of any prescription or nonprescription drugs, vitamins, herbal remedies, or dietary supplements within at least 14 days of entering the study.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 7-9 weeks.

    Cohort 1

    Clinic Stay

    • Participants will admit to Prism Clinical Research 2 times.
    • The first in clinic stay will last approximately 3 days (2 overnights).
    • The second in clinic stay will last approximately 11 days (10 overnights).

    Return Clinic Visits

    • There are 7 morning return clinic visits.

    Cohort 2

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in clinic stay will last approximately 9 days (8 overnights).

    Return Clinic Visits

    • There is 1 morning return clinic visit.

    Compensation for participation time:

    Cohort 1 Up to $3675.00

    Cohort 2 Up to $ 2150.00

    For information regarding this study contact Lindsay at: 651-368-3360 lindsayd@prismresearchinc.com or Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1710 (Part 2): Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at least one month prior to screening

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 13 weeks. 

    Clinic Stay

    • Individuals participating in the inpatient portion of the study will be confined at Prism Clinical Research one time during the study period for 8 days and (7 nights)

    Return Clinic Visits

    • Individuals participating in the inpatient portion of the study will return to the clinic for 4 outpatient visits (not including screening) and 1 telephone follow up call.
    • Individuals participating in the outpatient portion of this study will have 7 outpatient clinic visits (not including screening) and 1 telephone follow up call.

     

    Screenings begin:10/23/2017

    Anticipated start date for Study 1710 (Part 2): 6Nov2017

    Compensation for participation time:

    • If you participate is in the inpatient portion of the study, up to $2800.00 upon completion of all clinic visits and follow-up phone call.
    • If your participation does not require you to participate in the inpatient portion of the study, up to $1075.00 upon completion of all clinic visits and follow-up phone call.

     

     

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

     

  • Study 1717 Males and Females with Severe Renal Impairment

    Research Purpose: To evaluate the safety and tolerability of an investigational drug in individuals with renal impairment compared with individuals without renal impairment.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women must be postmenopausal or of non-childbearing potential

    Age

    18-75 years of age

    Body Mass Index (BMI)

    BMI between 18-40 kg/m² , and weigh a minimum of  50 kg (110 lbs)

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes in excess of 20 cigarettes per day or the equivalent during study participation.

    Health History

    Volunteers with severe renal impairment must be on a stable medication regimen and in good health consistent with renal impairment diagnoses.

     

    Healthy volunteers will not have renal impairment, and are not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the check-in and negative drug screen at screening and check-in.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 38 days

    Clinic Stay

    • Participants will be admitted to Prism Clinical Research.The in clinic stay will last approximately 5 days (4 overnights)

    Outpatient Visits

    • There is 1 clinic visit approximately 10 days following last dose of study drug.

    Compensation for participation time: Up to $1425.00

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Study 1719 Males and Females with Mild to Moderate Liver Impairment

    Research Purpose: To evaluate the absorption/elimination rate and safety/tolerability of an investigational drug being developed for the treatment high cholesterol.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-65 years of age

    Body Mass Index (BMI)

    BMI between 18-35 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes, or smoking cessation products 4 hours before and after receiving study drug.

    Health History

    For healthy volunteers: must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    For volunteers with mild/moderate liver impairment in good health consistent with liver impairment

    Alcohol/Drug Abuse History

    No History of drug or alcohol abuse within 6 months before the check-in and negative drug screen at screening and Check-in.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 45 days

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in clinic stay will last approximately 12 days (11 overnights)

    Outpatient Visits

    • There are no clinic visits following the discharge from the clinic.

    Compensation for participation time: Up to $3,000.00

     

    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

                                    

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • 1711: Vaccine Study (December 2017)
    • Studies for volunteers with Overactive Bladder
    • Studies for healthy males and females (2018)
    • Studies for volunteers with Herpes
    • Hepatic Study (February 2018)

    To be put on the call list and receive more information, when available, please contact Dayna at daynas@prismresearchinc.com or Lindsay at lindsayd@prismresearchinc.com.

Current Studies

Contact a Recruiter

  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 

    We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

     

    Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Currently, study 1719 is available. Please contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • **Freelancers Wanted**

    Freelancers, participate in a research study at Prism Research and earn extra income while completing your freelance projects in our comfortable facility by participating in one of our many research studies. If you're 18 - 60, healthy and have a flexible schedule, Prism Research has several current and upcoming FDA Approved Studies for you to consider. 

    Participants will receive health examinations and blood tests at no charge, meals and compensation ranging from $900 to $3,500 (or more) for study participation time. 

    Call for more information if you:
    � Currently Live in Minnesota or Western Wisconsin
    � Have Flexibility To Work Remotely
    � Want to Earn Extra Income

    *Interested in learning more about what clinical research studies are available? Reply or call Lindsay, Recruitment Coordinator at (651) 368-3360.

    Located in St. Paul

     

    Register in the database here

     

  • Study 1620: Male and Female Participants with Atopic Dermatitis

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed to treat subjects who have moderate to severe Atopic Dermatitis.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure Women with tubal ligation or bilateral salpingectomy if willing to use an acceptable method of contraception, or women of child bearing potential using acceptable forms of birth control are allowed to participate.

    Age

    18-70 years

    Body Mass Index (BMI)

    Between 17.5 – 38.0 kg/m²

    Body Weight

    Total body weight >50 kg (110 lbs).

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must have moderate to severe Atopic Dermatitis

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for at least 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research four times for a 4-hour period of study drug administration.

    Clinic Visits

    • There are up to 15 outpatient clinic visits, including screening

    Compensation for participation time:   Up to $1965.00 for approximately 15 visits

    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements

    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits

    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

  • Study 1718 Healthy Female and Male Participants NEW DATES ADDED

    Research Purpose: To evaluate how one drug interacts with an investigational drug being developed for the treatment of certain types of cancers.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate and must use acceptable birth control.

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women using an acceptable method of birth control are allowed to participate.

    Age

    18-55 years of age

    Weight/Body Mass Index (BMI)

    BMI between 18-30 kg/m²

    Tobacco/Nicotine Use

    Subjects must not have used tobacco or tobacco containing products, more frequently than 5 cigarettes per week within 2 months prior to screening or anytime within the week before screening and throughout the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Medications

    No use of any prescription or nonprescription drugs, vitamins, herbal remedies, or dietary supplements within at least 14 days of entering the study.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 7-9 weeks.

    Cohort 1

    Clinic Stay

    • Participants will admit to Prism Clinical Research 2 times.
    • The first in clinic stay will last approximately 3 days (2 overnights).
    • The second in clinic stay will last approximately 11 days (10 overnights).

    Return Clinic Visits

    • There are 7 morning return clinic visits.

    Cohort 2

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in clinic stay will last approximately 9 days (8 overnights).

    Return Clinic Visits

    • There is 1 morning return clinic visit.

    Compensation for participation time:

    Cohort 1 Up to $3675.00

    Cohort 2 Up to $ 2150.00

    For information regarding this study contact Lindsay at: 651-368-3360 lindsayd@prismresearchinc.com or Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1710 (Part 2): Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at least one month prior to screening

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 13 weeks. 

    Clinic Stay

    • Individuals participating in the inpatient portion of the study will be confined at Prism Clinical Research one time during the study period for 8 days and (7 nights)

    Return Clinic Visits

    • Individuals participating in the inpatient portion of the study will return to the clinic for 4 outpatient visits (not including screening) and 1 telephone follow up call.
    • Individuals participating in the outpatient portion of this study will have 7 outpatient clinic visits (not including screening) and 1 telephone follow up call.

     

    Screenings begin:10/23/2017

    Anticipated start date for Study 1710 (Part 2): 6Nov2017

    Compensation for participation time:

    • If you participate is in the inpatient portion of the study, up to $2800.00 upon completion of all clinic visits and follow-up phone call.
    • If your participation does not require you to participate in the inpatient portion of the study, up to $1075.00 upon completion of all clinic visits and follow-up phone call.

     

     

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

     

  • Study 1717 Males and Females with Severe Renal Impairment

    Research Purpose: To evaluate the safety and tolerability of an investigational drug in individuals with renal impairment compared with individuals without renal impairment.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women must be postmenopausal or of non-childbearing potential

    Age

    18-75 years of age

    Body Mass Index (BMI)

    BMI between 18-40 kg/m² , and weigh a minimum of  50 kg (110 lbs)

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes in excess of 20 cigarettes per day or the equivalent during study participation.

    Health History

    Volunteers with severe renal impairment must be on a stable medication regimen and in good health consistent with renal impairment diagnoses.

     

    Healthy volunteers will not have renal impairment, and are not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the check-in and negative drug screen at screening and check-in.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 38 days

    Clinic Stay

    • Participants will be admitted to Prism Clinical Research.The in clinic stay will last approximately 5 days (4 overnights)

    Outpatient Visits

    • There is 1 clinic visit approximately 10 days following last dose of study drug.

    Compensation for participation time: Up to $1425.00

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Study 1719 Males and Females with Mild to Moderate Liver Impairment

    Research Purpose: To evaluate the absorption/elimination rate and safety/tolerability of an investigational drug being developed for the treatment high cholesterol.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-65 years of age

    Body Mass Index (BMI)

    BMI between 18-35 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes, or smoking cessation products 4 hours before and after receiving study drug.

    Health History

    For healthy volunteers: must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    For volunteers with mild/moderate liver impairment in good health consistent with liver impairment

    Alcohol/Drug Abuse History

    No History of drug or alcohol abuse within 6 months before the check-in and negative drug screen at screening and Check-in.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 45 days

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in clinic stay will last approximately 12 days (11 overnights)

    Outpatient Visits

    • There are no clinic visits following the discharge from the clinic.

    Compensation for participation time: Up to $3,000.00

     

    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

                                    

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • 1711: Vaccine Study (December 2017)
    • Studies for volunteers with Overactive Bladder
    • Studies for healthy males and females (2018)
    • Studies for volunteers with Herpes
    • Hepatic Study (February 2018)

    To be put on the call list and receive more information, when available, please contact Dayna at daynas@prismresearchinc.com or Lindsay at lindsayd@prismresearchinc.com.

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel